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ypertrophic cardiomyopathy (HCM) is an autosomal
ominant disease of the cardiac sarcomere characterized
linically by generalized or localized hypertrophy of the left
entricle. Clinical manifestations of the disease vary, rang-
ng from no symptoms to heart failure, syncope, or sudden
ardiac death (SCD). Regarding the latter, clinical decision
aking is driven by the effectiveness of implantable defi-
rillators at ending arrhythmia (1), and the devastating
otential outcome of a sustained ventricular arrhythmia
vent (2–4). However, defibrillator implantation can be
ssociated with complications and low quality of life (5,6),
nd is not feasible for all patients with HCM. To identify
igh-risk candidates, risk factors including family history of
CD (7), syncope (8), nonsustained ventricular tachycardia
See page 1369
NSVT) (9–11), abnormal blood pressure response to ex-
rcise (12), and severe left ventricular hypertrophy (13) have
een proposed. Despite the application of such risk factors
o patient selection, a high proportion of current defibrilla-
or recipients never need a shock, and SCD continues to
ccur in many undiagnosed patients (14).
ationale for Using
ardiovascular Magnetic Resonance
ardiovascular magnetic resonance (CMR) recently has
een shown to predict induciblity of ventricular arrhythmia
n ischemic (15,16) and nonischemic (17) cardiomyopathies.
here is also accumulating evidence that CMR may predict
pontaneous clinical arrhythmia and SCD (18,19). Pathol-
gy studies in which hearts of patients with HCM were
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or theT
merican College of Cardiology.
From the Johns Hopkins Hospital, Baltimore, Maryland.xamined after death or transplantation have shown greater
xtent of fibrosis in patients with NSVT (20). Therefore, it
s plausible that the presence and extent of scar on CMR
ould predict arrhythmia risk.
In the current issue of the Journal, Adabag et al. (21)
resent results that suggest the utility of CMR for identi-
cation of HCM patients with increased susceptibility to
entricular arrhythmia. The authors correlated arrhythmic
vents on 24-h Holter monitoring of 177 HCM patients to
he presence of scar on CMR. Patients with any pattern of
car were found to have more premature ventricular con-
ractions and NSVT. The authors conclude that CMR may
dentify patients with increased susceptibility to ventricular
achyarrhythmia. These results are in agreement with earlier
tudies. Similar to the findings reported by Adabag et al.
21), Teraoka et al. (22) found higher occurrence of scar and
significantly larger extent of scar in HCM patients with
SVT. Dimitrow et al. (23) also reported lower likelihood
f scar in patients without NSVT compared with those with
SVT.
mplications for Risk Stratification
he use of surrogates of SCD as end points for studies of
isk stratification methodology is suboptimal and may lead
o incorrect estimates of association. However, until long-
erm survival data have been collected, these findings may
rovide additional data for selection of high-risk patients.
o apply these results to clinical patient care, an estimate of
he magnitude of increased risk for SCD in HCM patients
ith scar on CMR may be beneficial.
Probability theory provides a conceptual framework to
se gathered evidence toward the probability estimation of
ependent events. In the absence of long-term survival data,
e can mathematically approximate the probability of SCD
iven the presence of scar on CMR (P (SCD|CMR)) by
he following formula:
(SCD|CMR)
 (P(SCD|NSVT)P(NSVT|CMR))
 (P(SCD|NSVT)P(NSVT|CMR))
Similarly, the probability of SCD without the presence of
car on CMR (P(SCD|CMR)) can be approximated by
his formula:
(SCD|CMR)
 (P(SCD|NSVT)P(NSVT|CMR))
 (P(SCD|NSVT)P(NSVT|CMR))
In HCM patients, the 5-year probability of SCD given
SVT (P(SCD|NSVT)) and the probability of SCD in
he absence of NSVT (P(SCD|NSVT) have been pre-
iously reported to be 22.4% and 5.9%, respectively (10).
he current study reports the probability of NSVT given
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Editorial Comment April 8, 2008:1375–6car on CMR (P(NSVT|CMR)) and the probability
f NSVT given lack of scar on CMR (P(NSVT|
MR)) to be 28% and 4%, respectively. The probability
f lack of NSVT despite scar on CMR (P(NSVT|
MR)) is then 100%  28%  72%. Similarly, the
robability of lack of NSVT given lack of scar on CMR
P(NSVT|CMR)) is 100%  4%  96%. So, the
-year probability of SCD given the presence of scar on
MR is approximately:
P(SCD|CMR)  (0.224  0.28)  (0.59  0.72)  0.11
And the 5-year probability of SCD without the presence
f scar on CMR is approximately:
P(SCD|CMR)  (0.224  0.04)  (0.59  0.96)  0.07
Therefore, in the absence of long-term data, we would
pproximate the 5-year probability of sudden death to be
.6-fold higher if scar is noted on CMR of a patient with
CM. Extrapolation to the prevalence of HCM in the
eneral population (2 out of 1,000 young adults) (24),
uggests that identification of high-risk patients with CMR
ay have important consequences. Because CMR can
ccurately diagnose and characterize HCM, its added po-
ential for arrhythmic risk stratification may suggest its use
n place of echocardiography for the initial evaluation of
atients with suspected disease and preserved renal function
estimated glomerular filtration rate 30 ml/min/1.73 m2).
Cardiovascular magnetic resonance appears to be a prom-
sing tool for identification of the substrate underlying
entricular arrhythmia in structural heart disease (15–19).
his issue of the journal presents evidence in support of
sing CMR for risk stratification of arrhythmia in patients
ith another high-risk structural heart disease. Future
tudies of long-term survival in HCM patients stratified by
MR characteristics are warranted.
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-mail: snazarian@jhmi.edu.
EFERENCES
1. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-
defibrillators and prevention of sudden cardiac death in hypertrophic
cardiomyopathy. JAMA 2007;298:405–12.
2. Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported
survival rates in patients with hypertrophic cardiomyopathy. Heart
2006;92:785–91.
3. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ.
Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome
in an unselected regional population. J Am Coll Cardiol 1995;26:
1529–36.
4. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with
hypertrophic cardiomyopathy successfully resuscitated after cardiac
arrest. J Am Coll Cardiol 1989;13:1283–8.5. Schron EB, Exner DV, Yao Q, et al. Quality of life in the Antiar-
rhythmics Versus Implantable Defibrillators trial: impact of therapyand influence of adverse symptoms and defibrillator shocks.
Circulation 2002;105:589–94.
6. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-
blockers, amiodarone plus beta-blockers, or sotalol for prevention of
shocks from implantable cardioverter defibrillators: the OPTIC study:
a randomized trial. Jama 2006;295:165–71.
7. Maron BJ, Lipson LC, Roberts WC, Savage DD, Epstein SE.
“Malignant” hypertrophic cardiomyopathy: identification of a sub-
group of families with unusually frequent premature death. Am J
Cardiol 1978;41:1133–40.
8. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on
Sudden Cardiac Death of the European Society of Cardiology. Eur
Heart J 2001;22:1374–450.
9. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic signifi-
cance of 24 hour ambulatory electrocardiographic monitoring in
patients with hypertrophic cardiomyopathy: a prospective study. Am J
Cardiol 1981;48:252–7.
0. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M,
McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic
cardiomyopathy: an independent marker of sudden death risk in young
patients. J Am Coll Cardiol 2003;42:873–9.
1. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ.
Spectrum and prognostic significance of arrhythmias on ambulatory
Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll
Cardiol 2005;45:697–704.
2. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP,
McKenna WJ. Prospective prognostic assessment of blood pressure
response during exercise in patients with hypertrophic cardiomyopa-
thy. Circulation 1997;96:2987–91.
3. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ.
Magnitude of left ventricular hypertrophy and risk of sudden death in
hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778–85.
4. Maron BJ, Carney KP, Lever HM, et al. Relationship of race to
sudden cardiac death in competitive athletes with hypertrophic car-
diomyopathy. J Am Coll Cardiol 2003;41:974–80.
5. Bello D, Fieno DS, Kim RJ, et al. Infarct morphology identifies
patients with substrate for sustained ventricular tachycardia. J Am Coll
Cardiol 2005;45:1104–8.
6. Schmidt A, Azevedo CF, Cheng A, et al. Infarct tissue heterogeneity
by magnetic resonance imaging identifies enhanced cardiac arrhythmia
susceptibility in patients with left ventricular dysfunction. Circulation
2007;115:2006–14.
7. Nazarian S, Bluemke DA, Lardo AC, et al. Magnetic resonance
assessment of the substrate for inducible ventricular tachycardia in
nonischemic cardiomyopathy. Circulation 2005;112:2821–25.
8. Yan AT, Shayne AJ, Brown KA, et al. Characterization of the
peri-infarct zone by contrast-enhanced cardiac magnetic resonance
imaging is a powerful predictor of post-myocardial infarction mortal-
ity. Circulation 2006;114:32–9.
9. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic
resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am
Coll Cardiol 2006;48:1977–85.
0. Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ.
Relation between myocyte disarray and outcome in hypertrophic
cardiomyopathy. Am J Cardiol 2001;88:275–9.
1. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency
of arrhythmias in hypertrophic cardiomyopathy in relation to delayed
enhancement on cardiovascular magnetic resonance. J Am Coll Car-
diol 2008;51:1369–74.
2. Teraoka K, Hirano M, Ookubo H, et al. Delayed contrast enhance-
ment of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging
2004;22:155–61.
3. Dimitrow PP, Klimeczek P, Vliegenthart R, et al. Late hyperenhance-
ment in gadolinium-enhanced magnetic resonance imaging: compar-
ison of hypertrophic cardiomyopathy patients with and without non-
sustained ventricular tachycardia. Int J Cardiovasc Imaging 2008;24:
77–83.
4. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE.
Prevalence of hypertrophic cardiomyopathy in a general population of
young adults. Echocardiographic analysis of 4111 subjects in the
CARDIA Study. Coronary Artery Risk Development in Young
Adults. Circulation 1995;92:785–9.
